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Introduction
High-acuity vision is dependent on the cone photoreceptor visual 
pathway in all species with macular function. In humans with 
retinal disease, the final common pathway of visual acuity loss is 
cone photoreceptor dysfunction, or the pathway carrying cone- 
mediated information. Most cases of retinal blindness in the popu-
lation are age related, secondary to systemic metabolic disorders, or 
due to retinal vascular disease. Since damage to cone photorecep-
tors underlies the mechanism of visual acuity loss in each of these 
processes, understanding the biology of this retinal cell type is para-
mount to promoting retinal health and preserving vision. One of the 
most valuable sources of information regarding cone photoreceptor 
biology is the disease circumstance in which cones malfunction.
Cone disorders can be classified into achromatopsia, cone 
dystrophy, cone-rod dystrophy, color vision impairment, and mac-
ular dystrophies such as Stargardt disease. Phototransduction is 
the most commonly affected cellular process in cone disorders. 
This process depends on at least 10 genes that code for proteins in 
photoreceptor outer segments. Other cellular processes that can 
go awry in cone disorders include photoreceptor development, 
membrane morphogenesis and maintenance, protein trafficking 
to the outer segment, cellular signal transduction, or the recy-
cling of photopigment in the visual cycle. Achromatopsia is caused 
by mutations in cone phototransduction machinery. Greater 
than 90% of achromatopsia cases can be explained by causative 
mutations in the 5 genes implicated in this disease (1). However, 
cone-rod dystrophies, though associated with 17 different genes 
(2), can be attributed to a specific causative mutation in only 21% 
of clinical cases. Similarly, 8 cone dystrophy genes have been 
identified, but these explain only 25% of clinical diagnoses (3).
At least 42 genes have been identified that disrupt cone func-
tion, and mouse models are available for the majority of these 
(3). About half of the mouse models have had therapeutic strat-
egies evaluated. Accordingly, some progress has been made in 
understanding the pathophysiology of disease in a variety of 
cone disorders. However, no disease models exist in the context 
of high-acuity vision. The central human retina has a high cone 
density, which the mouse lacks, while outside of the central 10 
degrees, the rod-to-cone ratio is similar in both species (4). Fur-
thermore, mice and other nonprimate mammals such as cats 
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the descendants of a common founder, have characteristic signs, 
symptoms, and functional testing results that parallel humans 
with PDE6C-related cone photoreceptor disease.
Results
Visually impaired rhesus macaques show signs of achromatopsia. 
The Population and Behavioral Health Services (PBHS) staff 
at CNPRC observed behaviors attributed to visual compro-
mise in 4 rhesus macaques (3 females and 1 male, ages 2–11 
years). These primates had similar signs of visual compromise, 
including decreased ability to navigate new environments and 
subsequently using their forelimbs to feel for walls and obsta-
cles. When the primates were housed in smaller enclosures that 
were familiar to them, their visual impairment was less obvious. 
These macaques appear to elicit tolerant responses from their 
group members to behaviors that would normally trigger antag-
onism (e.g., direct gaze at close proximity). When housed in 
groups in large enclosures, some of these subjects were observed 
to be led by unaffected members holding their hand. Behavioral 
abnormalities such as eye poking and saluting (covering a por-
tion of the eye with the hand to decrease the visual stimulus) 
were also observed. The aforementioned behaviors were par-
ticularly evident when the animals were in normal illumination 
and dogs all lack macular architecture. The macula is a cone-rich 
specialized retinal structure that is the source of all high-acuity 
visual functioning. Macular structure and function are most sim-
ilar between humans and nonhuman primates (NHPs). Thus, 
NHP models of macular disease are highly desirable. Examples 
of individual NHPs with presumed inherited retinal disease have 
been described, but no genetic cause has been reported (5, 6). 
We are not aware of any previous studies of NHP retinal degen-
eration in which the causative mutation has been identified. 
There have been very few validated NHP models of Mendelian 
genetic disorders reported in the literature (7–10). Herein, we 
report severe vision impairment secondary to a homozygous 
missense mutation (R565Q) in the catalytic domain of the 
cone-specific phosphodiesterase 6α enzyme, encoded by the 
PDE6C gene in rhesus macaques from the California National 
Primate Research Center (CNPRC) at UC Davis. Originally iden-
tified by behavioral tests and observations, we report their adap-
tive behaviors, ocular examination findings, results of advanced 
ophthalmic imaging, and retinal electrophysiology. Further-
more, we report the genetic screening, identification of the caus-
ative mutation, predicted structural abnormality in the enzyme, 
stability of the protein product in vitro, and degree of biochemical 
function. These animals, genealogically related and presumably 
Figure 1. Visually impaired rhesus 
macaques have electroretinography 
tracings characteristic of achromatopsia. 
An example of an electroretinogram 
(ERG) tracing from the eye of an unaf-
fected macaque (A) is shown. Normal 
amplitude and latency is observed in the 
control case in both the rod-mediated (A, 
top row; dark adapted state, 0.01 cd•s/m2 
stimulus) and cone-mediated pathways 
(A, bottom row; light adapted state, 3.0 
cd•s/m2 stimulus). Affected subjects 
(B–E) noted to have visual impairment 
have relatively normal rod-mediated 
waveforms with perhaps subnormal 
amplitudes (B–E, top row). By contrast, 
affected animals (B–E, bottom row) 
have nonmeasurable cone-mediated 
recordings at 2 (B), 3 (C), 4 (D), and 11 (E) 
years of age, respectively. Green traces 
indicate initial testing. Orange lines indi-
cate repeated testing during the same 
recording session. μV: microvolts, ms: 
milliseconds.
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Furthermore, a subtle but characteristic bullseye maculopa-
thy was identified in the affected macaques (Figure 3, G–J) using 
fluorescein angiography (FA). This was not present in control sub-
jects (Figure 3F). The macular abnormalities were also seen using 
blue fundus autofluorescence (FAF) (Figure 3, L–N) in affected 
macaques, whereas control subjects had normal FAF (Figure 3K). 
The abnormal foveal appearance on color fundus photographs, FA, 
and FAF were corroborated using spectral-domain optical coher-
ence tomography (SD-OCT). The foveal center-point thickness 
(red caliper in Figure 4A), was reduced in affected subjects when 
quantitatively compared with controls (Figure 4B). This measure-
ment confirmed the clinical suspicion of foveal thinning in affected 
subjects based on the pronounced appearance of the foveal RPE. In 
order to determine which layers of the retina were affected, semi-
automated segmentation of the parafoveal region was performed 
on horizontal foveal b-scans (Figure 5B). Comparison of affected 
subjects with controls revealed that the global retinal thinning 
results from thinning of the outer nuclear layer (ONL) and photo-
receptor outer segments (Figure 5A). There were no statistically 
significant differences in the other retinal layers (Table 1). In aggre-
gate, these findings support the clinical diagnosis of achromatopsia 
in the visually impaired rhesus macaques at CNPRC.
Affected macaques are homozygous for a missense mutation 
in PDE6C. DNA was extracted from blood samples from the 4 
affected subjects and 2 of these subjects were sequenced using 
next generation sequencing technology. Based on the clinical 
diagnosis, attention was focused on a list of 43 candidate non-
syndromic cone disorder genes (3). Sequencing results and con-
firmatory genotyping revealed that all 4 affected subjects were 
homozygous for the same missense genetic variant in one of the 
candidate genes, PDE6C, which codes for the alpha-prime subunit 
of cone phosphodiesterase 6C. This protein hydrolyzes intracellu-
lar cyclic GMP (cGMP) and thus causes cGMP-gated channels to 
close and the photoreceptor plasma membrane to hyperpolarize, 
which is critical to the phototransduction cascade. The mutation 
changes an arginine to a glutamine at position 565 (R565Q). This 
alteration is within the catalytic domain of the enzyme, and spe-
cifically within the first metal binding motif 562HNWRH566, which 
is critical in all PDE families for hydrolysis of cyclic nucleotides. 
Moreover, the arginine at position 565 itself is highly conserved 
across vertebrates (Figure 6C), not only in PDE6 but also in other 
PDEs such as PDE5 (Supplemental Figure 2), suggesting it is play-
ing an important functional role (Figure 6, A and B). A model of 
settings such as outdoor daylight or indoor fluorescent lighting. 
These observations prompted the PBHS staff to perform addi-
tional behavioral testing and to request that the veterinary staff 
examine these primates for ocular disease. Thus, 2 affected rhe-
sus macaques and 2 age-matched control animals were placed in 
unfamiliar indoor enclosures under bright light conditions. The 
control animals were able to easily identify perches above them 
and food items such as grapes on the floor. By contrast, visually 
impaired subjects in the unfamiliar enclosure were found to 
avoid the floor, cover their eyes under normal indoor illumina-
tion conditions, and use their hands to confirm the presence of 
physical objects around them (Supplemental Video 1; supple-
mental material available online with this article; https://doi.
org/10.1172/JCI123980DS1).
Four affected macaques and 4 control subjects were sedated 
and received eye examinations involving clinical tests and imag-
ing similar to those performed on human patients in the UC Davis 
Eye Center. Eye examinations in all subjects revealed symmetric 
pupillary light reflexes and unremarkable anterior segments. The 
subjects were then dilated and dark adapted for electrophysiologic 
testing. Scotopic and photopic full-field electroretinograms (ERGs) 
were performed on controls (Figure 1A) and demonstrated normal 
rod and cone responses. The recordings from the affected subjects 
showed a relatively normal rod response, but a completely absent 
cone response (Figure 1, B–E). When combining the responses of 
the visually impaired animals, a modest reduction in rod-mediated 
amplitudes discerned in these measurements did not reach statis-
tical significance (Figure 2, left). Predictably, the combined maxi-
mal response of the ERG under dark adapted conditions, a function 
of both rod- and cone-mediated pathways, was reduced owing to 
the absence of a cone-mediated contribution (Figure 2, center). 
The cone-specific amplitudes measured under light adaptation 
showed no recordable signal in affected subjects in the single-flash 
ERG and in the photopic flicker when compared with controls 
(Figure 2, right).
Rhesus macaques show clinical signs consistent with achromatop-
sia. Indirect ophthalmoscopy in affected animals revealed subtle 
posterior segment changes in affected subjects. In particular, the 
foveal center appeared more pigmented (Figure 3, B–E) when 
compared with control subjects (Figure 3A). This finding may be 
due to thinning of the fovea, which may lead to increased retinal 
translucency, and a more pronounced appearance of the underly-
ing retinal pigmented epithelium (RPE).
Figure 2. Quantitative comparison of electroretinography shows absent cone- 
mediated and subnormal rod-mediated amplitudes. The absolute value of the ERG 
amplitudes (μV: microvolts) of both a- and b-waves from control and affected subjects 
was quantified and is graphically depicted. Under dark adapted conditions, using 
a 0.01 cd•s/m2 stimulus, the rod system was tested and found to be subnormal in 
affected subjects when compared with unaffected controls. The rod and cone com-
bined ERG, measured under dark adapted conditions using a 3.0 cd•s/m2 stimulus, 
showed moderately reduced responses in affected subjects compared with controls. 
The cone-mediated pathway was tested in the light-adapted state using a single flash 
3.0 cd•s/m2 stimulus, and also a flicker (30 Hz) with the same stimulus and showed 
virtually undetectable responses in the affected subjects (n = 4 in each group, *P < 
0.05, Student’s t test). Whiskers represent minimum and maximum. Boxes represent 
interquartile range. Line represents the median, and dots represent data points. 
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annotated by dbNSFPv2.9 (Supplemental File 1). The correspond-
ing human variant is only found in one individual in heterozygous 
status out of 123,101 individuals in the gnomAD database (16), 
which can serve as a control data set, suggesting the mutation is 
extremely rare in the human population.
To further test the pathogenicity of this variant, segregation 
testing was performed. Consistent with the recessive inheri-
tance model, genotyping of the parents of 2 affected individuals 
demonstrated that both parents were carriers (heterozygous for 
the mutated allele) and multiple unaffected siblings are either 
heterozygous for the mutation or WT (Figure 7). As part of a study 
to sequence a panel of 285 genes associated with human inherited 
retinal degeneration in 2000 NHPs, we screened genomes of 
related NHPs for the mutation. Genotyping of additional indi-
viduals has identified a total of 16 rhesus macaques at CNPRC 
that are heterozygous for the mutation in PDE6C. This variant 
is rare (P = 0.003) in our database of 527 randomly ascertained 
rhesus macaques from US research colonies. Mutations in PDE6C 
are responsible for approximately 1% of achromatopsia cases in 
humans (17) and 1% of cone dystrophy patients (18).
human cone PDE6C based on the model of the rod PDE6 catalytic 
dimer (11) indicates that R565 likely interacts with the aspartate at 
position 513 (Figure 6B). Likewise, D513 is highly conserved in the 
PDE6 family (Figure 6C). An R to Q substitution is predicted to 
be deleterious by multiple in silico prediction software tools, such 
as Combined Annotation Dependent Depletion (CADD), Sorting 
Intolerant From Tolerant (SIFT), and Polymorphism Phenotyp-
ing (PolyPhen). With the LiftOver tool of UCSC Genome Browser 
(12) and ANNOVAR (13), the corresponding human variant was 
identified in chr10:95400271 G>A (GRCh37), NM_006204, 
exon13, c.G1694A, p.R565Q, and annotated. The R565Q variant 
alters an amino acid site highly conserved in vertebrates with a 
phyloP100way_vertebrate_rankscore of 0.79983, and a phast-
Cons100way_vertebrate_rankscore of 0.71417 (the scores are 
in the scale of 0 to 1, annotated by dbNSFPv2.9) (14, 15). The 
human mutation is considered damaging by 10 prediction algo-
rithms, including SIFT_phred (D), Polyphen2_HDIV_pred (D), 
Polyphen2_HVAR_pred (D), LRT_pred (D), MutationTaster_pred 
(D), MetaSVM_pred (D), MetaLR_pred (D), VEST3_rankscore 
(0.84943), PROVEAN_pred (D), CADD_raw_rankscore (0.93161), 
Figure 3. Noninvasive retinal imaging of affected visually impaired rhesus macaques shows evidence of slowly progressive macular atrophy consistent 
with achromatopsia. Color fundus photography (A–E), fluorescein angiography (F–J), and fundus autofluorescence (K–N) were obtained in unaffected 
control and affected visually impaired subjects. An example of a control subject is shown (A, F, K; age 9 years), demonstrating normal posterior pole find-
ings. The fundus photos of affected animals show a largely normal macular appearance, but with prominent foveal pigmentation (B–E). The fluorescein 
angiogram in affected subjects demonstrated normal retinal vasculature at ages 2 (G) and 3 years (H), but the appearance of a bullseye pattern of foveal 
staining surrounded by parafoveal hypofluorescence was evident by age 4 years (I), and even more obvious by age 11 years (J). Fundus autofluorescence 
shows normal macular autofluorescence at age 2 years (L). At age 3 years (M) there is prominent foveal hyperautofluorescence, and development of an 
annulus of hypoautofluorescence centered on the fovea by age 11 years (N) which corresponds to the bullseye pattern seen on fluorescein angiography. 
Imaging software failure precluded fundus autofluorescence in the 4-year-old subject. Color fundus images were taken with a 50 degree lens. Fluorescein 
angiography and fundus autofluorescence images were taken with a Heidelberg Spectralis device using the default image size of 30 degrees.
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PDE6CR565Q protein in both samples, with or without the 
presence of Pγ, albeit the level of PDE6CR565Q protein was 
reduced by about 2-fold compared with PDE6C (Figure 
8B). These findings suggest that PDE6CR565Q is translated 
into a relatively stable protein product that colocalizes 
with AIPL1 and Pγ in vitro in HEK293T cells. To assess 
the membrane distribution of R565Q in comparison to 
that of PDE6C, we used the fractionation scheme for 
HEK293T shown in Figure 8C. Association of PDE6 
with the membrane requires proper C-terminal isopre-
nylation of its catalytic subunits (19). Dissociation of 
PDE6 from photoreceptor membranes can be achieved 
by extraction with hypotonic buffer (20). The immu-
noblot analysis indicates that PDE6C and R565Q are 
distributed in comparable proportions between soluble 
and membrane fractions following extractions with iso-
tonic and hypotonic buffers.
In order to investigate the enzymatic consequences 
of the R565Q mutation, we used an assay to measure 
PDE6 activity in terms of hydrolysis of radiolabeled [3H]
cGMP (nmol cGMP/min/mg protein). The activities were 
measured in HEK293T cell lysates following transfec-
tion with plasmids coding PDE6C in combinations with 
AIPL1 and Pγ. We determined that mutant PDE6CR565Q 
had profoundly diminished enzymatic activity (indistin-
guishable from untransfected control cells) when com-
pared with WT PDE6C, even in the presence of AIPL1 
and Pγ (Figure 9). These findings support the conclusion 
that R565 is a critical amino acid in the catalytic domain 
required for proper enzymatic function of PDE6C.
Discussion
Achromatopsia presents in humans in infancy with pho-
tophobia, nystagmus, hemeralopia, absent color discrimination, 
and poor visual acuity. The ERG findings in humans show absent 
cone amplitudes with preservation of the rod-mediated pathway, 
though we note that reductions of the latter have been reported 
(21, 22). While the clinical fundus examination is usually normal, 
evidence suggests achromatopsia is not a stationary disease. Vari-
able degrees of subtle macular changes ranging from loss of the 
foveal reflex, macular pigmentation changes, and rarely atrophy 
of the RPE have been described (23). The findings on SD-OCT 
can be normal or exhibit variable degrees of disruption of the 
inner-segment/outer-segment junction (IS/OS junction) (i.e., the 
The R565Q mutation in PDE6C impairs enzymatic function. 
To test whether the R565Q allele affects PDE6C protein stability 
or function, in vitro assays were performed. Transfection of 
HEK293T cells with an expression plasmid containing cDNAs 
coding flag-tagged WT PDE6C or PDE6CR565Q showed similar 
localization of the protein in the intracellular compartment (Fig-
ure 8A). The expression pattern of AIPL1-HA (the molecular 
chaperone of PDE6C) and EGFP-Pγ (a small regulatory subunit 
of PDE6C) was similar in cells transfected with WT PDE6C or 
PDE6CR565Q (Figure 8A, Supplemental Figure 1). Immuno-
blots from lysates of these transfected cells showed PDE6C or 
Table 1. Quantification of thicknesses of retinal layers in control and affected subjects
Retinal layers Control average, μm Control SD, μm Affected average, μm Affected SD, μm P value
Total retinal thickness 271.9 24.58 195.8 26.96 <0.05
Inner plexiform layer 27.9 7.54 24.5 6.86 0.342
Inner nuclear layer 43.4 10.1 36.7 9.1 0.342
Photoreceptor (ONL + IS) 121 12.64 67.7 19.71 <0.05
Photoreceptor OS 39.4 2.18 31.7 1.5 <0.05
Average measurements of retinal layer thicknesses from horizontal scans through the foveal center from unaffected control and affected subjects. Standard 
deviation (SD) and P values using the Wilcoxon test are also shown. ONL: outer nuclear layer; IS: inner segments; OS: outer segments. n = 4 for each group.
 
Figure 4. Foveal thinning is observed in visually impaired affected rhesus macaques. 
Spectral domain optical coherence tomography (SD-OCT) of the foveal center is shown 
from a control animal and from the 4 affected animals with the PDE6CR565Q mutation. 
Quantification of the thickness of the foveal center (box plot, right), measured from the 
internal limiting membrane to Bruch’s membrane (red caliper in control panel). There is 
a trend toward foveal thinning with age among the 4 affected animals (123 μm at age 2 
years, 119 μm at age 3 years, 115 μm at age 4 years, 108 μm at age 11 years) (n = 4 in each 
group, *P < 0.05). Whiskers represent minimum and maximum. Boxes represent inter-
quartile range. Line represents the median, and dots represent data points.
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ellipsoid zone) (24–26). The foveal appearance in achromatopsia 
has been divided into 5 different SD-OCT patterns (27). The vari-
able SD-OCT appearances do not correlate with genotype or age 
of the patients, suggesting that modifying genes or environmen-
tal factors may be responsible for the phenotypic differences. In 
achromatopsia, FAF ranges from normal to hyper- or hypoauto-
fluorescence (28), and findings suggest that the macular changes 
can be progressive, with younger patients exhibiting hyperauto-
fluorescence, and older patients showing hypoautofluorescence 
(29). This is consistent with the general concept that hyperauto-
fluorescence is indicative of stressed RPE (30), and hypoautofluo-
rescence correlates with nonfunctional or absent RPE (31).
We present a spontaneously occurring NHP model of achro-
matopsia presenting very early in life (1 year, 10 months) caused by 
R565Q mutation of the PDE6C gene, altering the catalytic domain 
of the PDE6C enzyme and nullifying its enzymatic hydrolysis of 
cGMP. Similar to human patients, PDE6CR565Q macaques have 
un recordable cone responses on ERG. It is possible that the rod 
responses in NHPs may begin to decline later in the disease course 
(Figure 1E, top panel), which also occurs in human achromatopsia 
patients (32, 33), as well as in 37% of cone dystrophy patients with-
in 10 years of diagnosis (18). Hypotheses to explain the rod abnor-
malities have centered around fewer absolute numbers of rod pho-
toreceptors, decreased length of their outer segments, and altered 
rod photoreceptor circuitry (34). The degree to which rod-photo-
receptor dysfunction is present or develops in the affected NHPs 
reported here will be the subject of further study. As is typical in 
human cases, the clinical fundus appearance was relatively normal in 
PDE6CR565Q macaques, and the macular SD-OCT had a normal IS/
OS junction (ellipsoid zone). Consistent with prior reports of FAF 
in human achromatopsia, our younger subjects appeared to have 
hyperautofluorescent changes, while the oldest subject developed 
a bullseye appearance of hypoautofluorescence surrounding the 
foveal center. This may represent individual variability in the phe-
notype or may be indicative of disease progression. The tendency 
for FAF abnormalities to worsen with time in human patients, and 
the reduced rod amplitudes in our oldest subject, suggests that the 
latter explanation may be more likely. Our findings show that the 
PDE6CR565Q macaques exhibit typical signs of achromatopsia, and 
have examination findings, ophthalmic imaging, and ERG record-
ings characteristic of this condition.
The PDE6C protein is chaperoned to the cone outer segment 
by AIPL1 and Pγ where it ultimately joins the other subunits of 
the enzyme on outer segment disks, which are infoldings of the 
cone outer segment membrane (20, 35, 36). Mutations in this 
gene are associated with achromatopsia in several human ped-
igrees, accounting for about 1% of clinical cases (17). A similar 
fraction of cone dystrophy and cone-rod dystrophy has been 
attributed to a mutation in this gene as well (18, 37, 38). The 
genotype-phenotype variability in patients with PDE6C muta-
tions may be attributed to allelic differences, the effect of genetic 
modifiers, or environmental factors. In human subjects with 
PDE6C-associated achromatopsia, the fundus appears largely 
normal with subtle foveal pigmentary changes. Furthermore, the 
SD-OCT shows a thinned foveal center with localized hypore-
flectivity indicative of subretinal fluid. In addition, the FAF is 
altered and the ERG shows absent cone responses from an early 
age (39, 40). The phenotype of our affected subjects is identical 
to the human patients with PDE6C-associated disease, with the 
exception of the foveal hyporeflective lesion seen on SD-OCT. In 
patients with PDE6C-associated achromatopsia, mutations can 
lead to protein degradation, cellular mislocalization, or enzy-
Figure 5. Retinal thinning in affected visually impaired animals is due to cone photoreceptor loss. Comparing the topographical thickness of retinal lay-
ers in the parafoveal region (A, control blue, affected red) shows thinning of the retina. The reduced thickness is secondary to thinning in the outer nuclear 
layer and photoreceptor outer segments. The other retinal layers are of similar thickness to unaffected controls. The thickness of retinal layers was mea-
sured by semiautomated segmentation of SD-OCT horizontal scans through the foveal center (B, unaffected control left, affected right). Inner plexiform 
layer (IPL), inner nuclear layer (INL), outer nuclear layer (ONL + inner segments), photoreceptor outer segments (POS). n = 4 for each group.
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matic dysfunction (41). Consistent with human cases exhibiting 
mutations in the catalytic domain of this enzyme, the macaque 
PDE6CR565Q protein is transcribed, translated, is relatively stable, 
but is incapable of hydrolyzing cGMP.
PDE6CR565Q macaques are ideal for evaluation of thera-
peutic strategies for achromatopsia, and potentially for other 
related retinopathies. Small and large animal models of spon-
taneously occurring achromatopsia exist and have been used 
successfully for gene therapy (42). Many groups have reported 
the results of gene therapy strategies in animal models of 
achromatopsia. Gene replacement can improve the function 
of cone cells in achromatopsia mouse models with CNGB3- 
(43), CNGA3- (44–46), and GNAT2-associated disease (47). 
Treatment of dogs with achromatopsia secondary to CNGB3 
mutation have shown durable rescue of cone function after 
viral-mediated gene replacement for at least 33 months (48). 
Sheep with mutation in CNGA3 have also been successfully 
treated with a similar approach (49). As a result of these suc-
cesses in various animal models, phase I/II human clinical 
trials are in progress for CNGB3 (NCT02599922) and CNGA3 
(NCT02610582) achromatopsia using AAV-mediated deliv-
ery of these genes (50). No gene replacement studies have 
been published concerning PDE6C in any species to date. 
PDE6CR565Q NHPs could serve as an effective model not only 
to evaluate treatment of affected NHPs, but also to test and 
optimize viral-mediated treatment modalities by subretinal 
and intravitreal injection (51) of AAV2 carrying functional 
PDE6C. It may be worthwhile to perform preliminary stud-
Figure 6. The R565Q mutation in PDE6C alters a conserved arginine in the catalytic domain. (A) A model of human PDE6C protein dimer was generated 
using SWISS-MODEL based on the study by Zeng-Elmore et al. (11). The boxed portion is a catalytic domain and the R565 residue is highlighted (depicted 
in sphere, carbon in magenta). (B) Magnified view around residue R565 and its putative interaction with D513. R565 and D513 are shown as sticks, colored 
by element (carbon in magenta). Loop 509–516 is shown in cyan and helix 565–579 is shown in magenta. Catalysis-related residues are shown as sticks, 
colored by element (carbon in yellow). Zinc and magnesium ions are shown as red and blue spheres, respectively. Original data are from the Protein Data 
Bank (accession ID: 3jwr). (C) Protein sequence alignment shows that both D513 and R565 are highly conserved (boxed).
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humans and macaques than between humans and rodents (61). 
Furthermore, it has been demonstrated that rhesus macaques 
and humans share common susceptibility genes for age-related 
macular degeneration (AMD) and that cross-species genotype- 
phenotype correlations exist (62). The major challenge to using 
NHPs as models has been the lack of easy access to appropriate 
study subjects. NHPs, particularly Old World monkeys such as 
rhesus macaques, have been recognized as appropriate mod-
els for the study of ocular diseases (63). However, given the 
low prevalence of spontaneous disease, only a small number of 
individual animals are affected in even the largest research col-
onies, and their disease phenotype may go unrecognized. Recent 
reductions in the cost of DNA sequencing, and the resulting rev-
elations concerning the amount of functional genetic variation 
segregating in rhesus macaque research colonies, now make 
broad surveys of these colonies for genetic mutations that dis-
play a disease phenotype practical (64).
We have identified a cone dystrophy in rhesus macaques at the 
CNPRC, characterized by marked photopic vision impairment, 
progressive macular thinning by optical coherence tomography, 
and absent cone function by electroretinography. These animals 
are homozygous for a missense mutation altering the catalytic 
domain of their PDE6C proteins, a gene associated with achroma-
topsia or cone dystrophy in humans. This NHP model of a cone 
disorder will be useful for evaluating gene replacement, gene 
editing, and cell-based replacement strategies. Continued char-
acterization of the ophthalmic consequences and progression 
of disease in this IRD model, as well as expansion of this colony 
of macaques for the scientific community, will benefit various 
aspects of vision research. Identification of additional NHPs with 
spontaneously occurring IRDs constitutes an outstanding step 
forward that will generate new resources for further investigation. 
We anticipate that NHP models of retinal disorders will decrease 
ies in mice with spontaneous Pde6c mutations (17), or in 
Pde6cR565Q engineered mice. In addition to gene replace-
ment, PDE6CR565Q NHPs may be a good model in which to 
test CRISPR/Cas9-mediated base editing or homology 
directed repair (CRISPR-HDR) to produce a functional 
genome-derived enzyme. Since no other genetically character-
ized, spontaneously occurring, inherited retinal degeneration 
models exist in NHPs, PDE6CR565Q macaques may provide a 
good model to test CRISPR strategies once their efficiency and 
safety are elucidated.
Another possible application of this achromatopsia model 
takes advantage of the cone-silent state and relatively stable 
architecture of the macula to test cone replacement strategies. 
Cone replacement has suffered from challenges in the production 
of cone photoreceptors in vitro from retinal organoids, though 
some strategies have been reported to bias cells to adopt this fate 
(52–54). Cell transplantation to the retina is also undergoing a 
significant revitalization. The breakthroughs achieved in the last 
decade using mouse models (55) appear to be in part secondary 
to material transfer between transplanted cells and endogenous 
cells (56–58). Until recently, the eye was largely considered to 
be an immune privileged organ, but this notion is being chal-
lenged by recent studies showing that cell replacement strate-
gies are improved in the immune suppressed state (59, 60). The 
PDE6CR565Q macula may be an ideal testing ground for cone 
replacement, once the barriers of cone cell production and host 
immune suppression are overcome.
NHP models are particularly compelling due to their out-
standing anatomic, developmental, physiologic, social, and 
genetic similarity to humans. This tremendously increases the 
relevance and translational potential of these models. Macaques 
share approximately 93% DNA sequence similarity with 
humans, and protein sequences are much more similar between 
Figure 7. Pedigree of affected rhesus macaques. Partial pedigree of the 4 affected rhesus macaques (filled). Genotyping was conducted and all 4 affected 
subjects were determined to be homozygous for the R565Q mutation in PDE6C. In addition, 8 unaffected related individuals (arrows) were genotyped and 
are heterozygous carriers noted with a dot. Squares represent males, and circles represent females. Crossed line represents that the individual is no longer 
available within the colony. * Date of birth.
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group members. Ophthalmic phenotyping of these animals was 
performed in response to the behavioral observations suggestive of 
reduced visual functioning.
Ophthalmic phenotyping. Animals were sedated with intramuscu-
lar injection of ketamine hydrochloride and dexmedetomidine. Oph-
thalmic examination included pupillary light reflex testing, external 
and slit lamp examination, measurement of intraocular pressure, and 
dilated funduscopy and streak retinoscopy.
Ophthalmic imaging. Color fundus photography was performed with 
a CF-1 Retinal Camera with a 50° wide-angle lens (Canon). SD-OCT 
with confocal scanning laser ophthalmoscopy was performed (Spectra-
lis HRA+OCT). The Spectralis device was also used to obtain blue-peak 
fundus autofluorescence, as well as fluorescein angiography simultane-
ously with SD-OCT. The Heidelberg eye tracking Automatic Real-Time 
(ART) software was set at 25 scans for each b-scan. A horizontal high- 
resolution raster scan centered on the fovea was obtained. Semiautomat-
ed segmentation of retinal layers and foveal thickness measurements 
were performed on a horizontal line scan through the foveal center using 
a custom proprietary algorithm (EdgeSelect, EyeKor Inc.) and using the 
measurement tool in ImageJ (NIH), respectively. Animals were moni-
tored by a trained technician and a CNPRC veterinarian at all times.
Electroretinography. While sedated, animals were dilated and dark 
adapted for 30 minutes. The RETevet instrument (LKC Technologies) 
the time required and improve the success rate for translation of 
gene- or cell-based therapies to human clinical trials.
Methods
Animals. All the rhesus macaques (Macaca mulatta) studied were 
born and maintained at the California National Primate Research 
Center (CNPRC), which is accredited by the Association for Assess-
ment and Accreditation of Laboratory Animal Care (AAALAC) 
International. All guidelines of the Association for Research in 
Vision and Ophthalmology Statement for the Use of Animals in 
Ophthalmic and Vision Research were followed. All studies were 
in accordance to the National Institutes of Health (NIH) Guide for 
the Care and Use of Laboratory Animals (National Academies Press, 
2011). Ophthalmic examinations and phenotyping were performed 
according to an animal protocol approved by the Institutional Ani-
mal Care and Use Committee at UC Davis (IACUC protocol 20145). 
Standard procedures at the CNPRC involved routine physical exam-
inations, which took place every 6 months under sedation. Blood 
samples were drawn routinely and preserved at –20°C for each 
animal. The Population and Behavior Health Services staff at the 
CNPRC observed outdoor animals for 20–30 minutes twice a month 
using all occurrence sampling (65). These observations were then 
used to identify social dynamics and abnormal behaviors among 
Figure 8. Coexpression of PDE6C and R565Q with AIPL1 and Pγ in HEK293T 
cells. (A) Confocal immunofluorescence images of HEK293T cells cotransfected 
with PDE6C or R565Q (red, anti-PDE6C) and the AIPL1-Pγ vector (AIPL1: blue, 
anti-HA; Pγ: green, EGFP fluorescence). (B) Immunoblot analysis of extracts of 
HEK293T cells cotransfected with PDE6C or R565Q and AIPL1 or the AIPL1-Pγ 
vector using anti-Flag (PDE6C), anti-EGFP (P), and anti-HA (AIPL1) antibodies. 
Lanes contain equal amounts of protein. From 4 similar experiments, the level 
of R565Q protein expression is reduced to 57% ± 9% (mean ± SEM) of that for 
PDE6C. (C) Scheme of fractionation of lysates from HEK293T cells cotrans-
fected with PDE6C (or R565Q), AIPL1, and Pγ, and immunoblot analysis in the 
scheme fractions 1–5 with anti-Flag antibody. The findings suggest that the 
distributions of PDE6C and R565Q in HEK293T cells are qualitatively similar, 
but the amount of R565Q protein expression is reduced.
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EGFP-P (the AIPL1-P vector) were cloned into a mammalian expres-
sion vector, pcDNA3.1(+), as previously reported (20, 35). The R565Q 
mutation was introduced into the PDE6C vector using the Quik-
Change (Agilent) site-directed mutagenesis protocol provided by the 
manufacturer. The sequences of all constructs were verified by auto-
mated DNA sequencing at the University of Iowa DNA Core Facility.
Cell culture. HEK293T cells (293T, ATCC, CRL- 3216) were cul-
tured and maintained in DMEM containing 10% FBS (Thermo Fisher 
Scientific). Cells were cotransfected with pcDNA3.1(+) plasmids har-
boring either PDE6C and AIPL1 (1 μg each), or PDE6C and EGFP-Pγ 
(1 μg each), or PDE6C and the AIPL1-Pγ vector (1 μg each), using 
FuGene6 (Promega) according to the manufacturer’s instructions. 
Cells were collected 48 hours after transfection. Cell lysates, prepared 
in 20 mM Tris-HCl buffer (pH 7.5) containing 120 mM KCl and 1 mM 
MgCl2 and 1× EDTA-free protease inhibitor cocktail (Roche), were 
analyzed by immunoblotting for protein expression and assayed for 
PDE activity. For membrane fractionation, lysates of HEK293T cells 
cotransfected with PDE6C (or PDE6CR565Q ), AIPL1, and Pγ were pre-
pared in isotonic buffer (20 mM Tris-HCl buffer, pH 7.5, containing 
120 mM KCl and 1 mM MgCl2 and 1× EDTA-free protease inhibitor 
cocktail) and centrifuged at 125,000g for 30 minutes at 4°C in a Beck-
man Optima TLX Ultracentrifuge. The pellet thus obtained was fur-
ther resuspended in hypotonic buffer (5 mM Tris-HCl, pH 7.5, 1 mM 
MgCl2, and 1× EDTA-free protease inhibitor cocktail) and centrifuged 
at 125,000g for 30 minutes at 4°C to obtain hypotonic supernatant. 
The extracted pellet was resuspended in the same hypotonic buffer 
and homogenized in a 1.5-ml tube using a disposable pestle. For 
immunofluorescence, 48 hours after transfection cells were seeded 
onto poly-D-lysine–coated (MilliporeSigma) (0.1 mg/ml) 4-well 
chambered glass slides and allowed to grow for an additional 24 hours 
before fixation with 4% formaldehyde.
Immunoblotting. Proteins separated by 4%–12% SDS-PAGE were 
transferred to a nitrocellulose membrane using the iBlot Western blot 
kit (Invitrogen) and analyzed using mouse monoclonal anti-FLAG 
(MilliporeSigma, F3165-1MG, 1:2000 dilution), mouse anti-HA (Bio-
Legend, clone 16B12, catalog 901502, 1:1000 dilution), and mouse 
anti-GFP (Santa Cruz, SC-9996, 1:2000 dilution) primary antibod-
ies. The antibody-antigen complexes were detected using horseradish 
peroxidase–conjugated bovine anti-mouse (Santa Cruz, SC-2371, 
1:10,000 dilution) secondary antibody and enhanced chemilumi-
nescence (ECL) reagents obtained from GE Healthcare. PDE6C and 
PDE6CR565Q protein expression levels were quantified using analysis of 
immunoblot data with NIH ImageJ software according to the user guide.
Immunofluorescence. Transfected HEK293T cells on chambered 
glass slides were prepared for immunofluorescence as previously 
reported (20, 35). Briefly, fixed and permeabilized cells were blocked 
for 60 minutes in blocking solution (1% BSA in 1× PBS) and then incu-
bated at 4°C overnight with either rabbit anti-PDE6C (71) or mouse anti-
HA antibodies diluted in the blocking solution. After washes with PBS, 
cells were incubated in the dark for 1 hour in either Alexa Fluor 568–
conjugated goat anti-rabbit (Life Technologies, A-11011) or Alexa Fluor 
488–conjugated goat anti-mouse (Life Technologies, A-11017), or Alexa 
Fluor 647–conjugated F(ab’)2-goat anti-mouse IgG (H+L) secondary 
antibody (Thermo Fisher Scientific, A-21237) diluted in the blocking 
solution. After washes with PBS, where indicated, the nuclei were coun-
terstained with To-Pro-3 (Thermo Fisher Scientific) for 30 minutes in 
the dark at 25°C. Cells were mounted using Vectashield mounting medi-
coupled to an ERG-Jet electrode from the same vendor (item 95-011) 
was used to perform a standard flash ERG according to the approved 
protocol of the International Society for Clinical Electrophysiology 
of Vision (ISCEV) (66). This test consisted of electroretinography 
using flash stimuli at 0.01 cd•s/m2, 3.0 cd•s/m2, and 10.0 cd•s/m2, and 
oscillatory potentials (OPs), all in the dark-adapted state. In addition, 
flash stimuli of 3.0 cd•s/m2 intensity were used after 10 minutes in the 
light-adapted state, as well as a 30 Hz photopic flicker. Measurements 
were recorded and displayed using the manufacturer’s software.
Genetic sequencing and analysis. Whole-genome shotgun sequenc-
ing (WGS) was performed on 2 affected subjects following the protocol 
provided by the manufacturer. In brief, 1 μg genomic DNA was sheared 
using Covaris for 120 seconds and purified using Ampure XP beads. 
After end repair and A-tailing, indexed adaptors were added. The prod-
uct was purified using Ampure XP beads and amplified using KAPA Hifi 
HotStart ready mix. After bead purification, the library was diluted and 
loaded onto the Illumina Novaseq6000 Sequencer for sequencing.
Sequencing reads from the 2 rhesus macaques were aligned to the 
rhesus Mmul_8.0.1 reference genome assembly using BWA mem (67) 
with an average mapped sequence depth of ×44.6. The GATK pipe-
line (68) was used to identify single nucleotide variants (SNVs) and 
insertions/deletions (indels). Variant effect predictor (VEP) (69) was 
used to annotate variants based on merged Ensembl and RefSeq gene 
models. Variants of interest in genes known to be involved in cone dis-
orders (3) were identified for further analysis. The allele frequencies of 
the variants of interest were calculated for our reference database of 
whole-genome sequences from 537 rhesus macaques. The variants of 
interest were further examined by lifting the rhesus positions over to 
the orthologous human position and performing CADD analysis (70), 
which predicts the functional impact of variants. Direct PCR Sanger 
sequencing was conducted to further confirm the candidate mutation 
in PDE6C in each individual.
Plasmids/cloning. DNA sequences encoding the full-length human 
FLAG-PDE6C, mouse AIPL1-HA, EGFP-Pγ, and AIPL1-HA-IRES-
Figure 9. Catalytic activities of PDE6C and R565Q expressed in HEK293T 
cells. cGMP hydrolysis in extracts of HEK293T cells cotransfected with 
PDE6C or R565Q and AIPL1 alone or the AIPL1-Pγ vector (UN: untransfected  
control). Since Pγ is the inhibitory subunit of PDE6, the samples with 
coexpression of Pγ were treated with trypsin to selectively remove P (tr). 
The data suggest R565Q is catalytically inactive. The data were analyzed by 
1-way ANOVA with Tukey’s multiple comparisons follow-up test.  
Whiskers represent minimum and maximum. Boxes represent interquartile 
range. Line represents the median, and dots represent data points. Exact n 
shown in figure.
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extracts obtained from HEK293T cells 48 hours after transfection. 
Where indicated, samples were treated with 0.1 mg/ml TPCK-Trypsin 
(MilliporeSigma) on ice for 10 minutes to selectively degrade Pγ, after 
which trypsin was inhibited with the addition of 10-fold excess of soy-
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addition of AG1-X2 cation exchange resin (0.5 ml of 20% bed volume 
suspension). Samples were incubated for 6 minutes at 25°C with occa-
sional mixing, and spun at 10,000g for 3 minutes. A quantity of 0.25 ml 
supernatant was removed for counting in a scintillation counter.
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mated segmentation was compared quantitatively using the Wilcoxon 
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multiple comparisons follow-up test. In all cases, P values less than 
0.05 were deemed significant.
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